There has been a consensus that large biotechs are answerable to different commercial dynamics from large pharma. Amgen’s troubles are a good example of a possible convergent trend between big pharma and biotech. Amgen’s troubles appear to stem from very similar issues to those faced by large pharma and the solution may lie in the same strategies - collaborations, in-licensing and acquisitions. However changes in this perception and convergence between big pharma and biotechnology businesses are anticipated.